Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Biagioli

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
British Journal of Cancer|September 21, 2019
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancerNicoletta Colombo, Eleonora Zaccarelli, Alessandra Baldoni, et al.
Clinical Pharmacology and Therapeutics|May 27, 2023
Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and BevacizumabMaurizio Polano, Luca Bedon, Michele Dal Bo, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2026
Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49)Nicoletta Colombo, Gabriella Parma, Giulia Tasca, et al.
Journal of Gynecologic Oncology|July 1, 2025
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trialKenichi Harano, Roldano Fossati, Beatriz Pardo, et al.
Tumori|December 15, 2025
Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trialAlessio Carbone, Elena Biagioli, Vanda Salutari, et al.
The Lancet. Oncology|August 5, 2024
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trialNicoletta Colombo, Elena Biagioli, Kenichi Harano, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
British Journal of Cancer|September 21, 2019
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancerNicoletta Colombo, Eleonora Zaccarelli, Alessandra Baldoni, et al.
Clinical Pharmacology and Therapeutics|May 27, 2023
Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and BevacizumabMaurizio Polano, Luca Bedon, Michele Dal Bo, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2026
Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49)Nicoletta Colombo, Gabriella Parma, Giulia Tasca, et al.
Journal of Gynecologic Oncology|July 1, 2025
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trialKenichi Harano, Roldano Fossati, Beatriz Pardo, et al.
Tumori|December 15, 2025
Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trialAlessio Carbone, Elena Biagioli, Vanda Salutari, et al.
The Lancet. Oncology|August 5, 2024
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trialNicoletta Colombo, Elena Biagioli, Kenichi Harano, et al.
Pageof 4